Peptide News Digest

#Import-Alert

2 stories

Regulatory · View digest

FDA Inspectors Found Black Mold, Insects, and Discarded Samples at a Chinese Plant Making Semaglutide and Tirzepatide Ingredients for Compounding

FDA inspection reports obtained by Bloomberg through a Freedom of Information Act request describe black mold on equipment, "gross contamination" on floors, and "significant insect activity" in ceilings at Chengdu Shengnuo Biopharm in southwest China, inspected in August, where staff moved documents to lockers and poured product samples into sinks. A September inspection found that Nanjing Chengong Pharmaceutical had bought active ingredients from other factories and applied its own seal without reviewing their test data. FDA's Import Alert 66-40 lists Chengdu Shengnuo as of September 19, 2026 and Nanjing Chengong as of October 1, so their products can be detained at the U.S. border; the companies made semaglutide and tirzepatide ingredients used in compounded drugs.

Regulatory · View digest

FDA Warning Letter to Harbin Jixianglong Biotech (May 20): Chinese GLP-1 Supplier Shipped Semaglutide API Sourced From Non-Green-List Facility Under Misleading Label

The FDA sent a warning letter to Harbin Jixianglong Biotech disclosed May 20 after inspectors discovered a compliance failure at the company's manufacturing facility two months after the firm had been added to the FDA's green list to export GLP-1 drugs to the US. Jixianglong allegedly bought semaglutide active pharmaceutical ingredient from a facility not on the green list, labeled the API as manufactured at its own plant (implying the green-listed origin), and shipped the batch to US customers. The FDA framed the labeling as an apparent attempt to circumvent import-alert safeguards. The agency's March 11 enforcement report had previously listed Jixianglong recalls of semaglutide for compounding use only, attributed to failing to complete process validation and bacterial endotoxin method validation before distribution. The action is part of the broader FDA Pharmaceutical Quality / GLP-1 supply-chain enforcement cycle, including the April 30 503B bulks-list proposal closing June 29.